Research -

Open Access for Alfasigma’s scientific publications

October 22, 2025

Alfasigma has taken another step in its transformation journey by adopting an Open Access publication policy, ensuring that all company-sponsored and funded research is accessible barrier-free to ever...

Alfasigma R&D presents a new inhalable antibody able to block COVID19

April 10, 2022

Developed by the researchers of Labio 4.0 of Pomezia and University of Rome Tor Vergata, it has been obtained from the blood of doctors of the Hospital of Bergamo infected during the pandemic emergen...

Alfasigma inaugurates the new Research&Development center in Pomezia named after its founder Marino Golinelli

September 15, 2021

Over 17 million EUR invested in LABIO 4.0 Marino Golinelli Two days dedicated to Open Innovation and the promotion of young talent with a group of Spanish students winning Alfathon Day...

Alfasigma joins the global fight against COVID-19

April 1, 2020

From Italy, with European, Chinese and Iranian partners, the attempt to answer the questions generated by the SARS-CoV-2 virus: a genetic study at the basis of new diagnostic and therapeutic solutions...